January/February 2014: Volume 15 Number 1/2

htb janfeb14 coverWelcome to the first issue of HTB of 2014.

Conference reports in this issue kick of with the annual reports from the International Workshop on HIV & Women – now in it’s fourth year.

Giving a thought provoking start to the year, presentations reminded us that two decades into the epidemic, women are still underrepresented in HIV research and disparities in treatment outcomes need to be addressed.

A presentation at the 17th International Conference on AIDS and STIs in Africa showed that rates of discontinuation of efavirenz in African settings might be underestimated.

And, thanks to natap, David Margolis gives a brilliant overview of the complexities facing cure research discussed at the 6th International Workshop on HIV Persistence.

Recent European approvals include dolutegravir for HIV, sofosbuvir for hepatitis C (which was approved in the US a few weeks earlier) and bedaquiline for TB.

The BHIVA guidelines have also been updated, largely to comment on the choice of ARVs for preferred and alternative first-line therapy and to reflect the recommendations from the new hepatitis guidelines.

International news has the addition of atazanavir to the Patent Pool, more donations pledged to the Global Fund (but still falling short of the US$15 billion goal), and the Fund’s urgent request to Nigeria to reconsider their unjust and discriminatory new anti-gay law and its consequences.

Next issue will be dominated by reports from CROI 2014 – taking place in Boston this year from 3-6 March.

Contents in full.

BHIVA members – print copies of HTB

Please note that BHIVA members who are reading HTB electronically who want to continue to receive the print edition, need to subscribe online at:

Or send your name, position, organisation and full postal address details to:

Notice of error

The PDF file distributed for the November/December edition of HTB included an error that was corrected for the print and online editions. The roll-over arm in the LATTE study should have referred to maintenance therapy usual the oral formulation rather than injections. We apologise for this error.

Links to other websites are current at date of posting but not maintained.